2-(2-苯氧基乙氧基)-苯甲酸 | 101093-93-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-苯氧基乙氧基)-苯甲酸
• 中文别名: 2-(5-(1-三苯甲基-1H-四氮唑)苯硼酸
• 英文名称: 2-(2-phenoxyethoxy)benzoic acid
• CAS: 101093-93-0
• 化学式: C₁₅H₁₄O₄
• 分子量: 258.274
• InChiKey: XTODKUCZLUADDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-(2-苯氧基乙氧基)-苯甲酸 以42%的产率得到N'-[1-imidazol-1-yl-1-[2-(2-phenoxyethoxy)phenyl]methylidene]-N,N-dimethylhydrazine
  参考文献：
  名称：

  EP2168951

  摘要：

  公开号：
• 作为产物：
  描述：

  水杨酸乙酯 在 sodium hydroxide 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 109.5h， 生成 2-(2-苯氧基乙氧基)-苯甲酸
  参考文献：
  名称：

  来自人类免疫缺陷病毒的蛋白酶的抑制剂：一系列含有二羟基乙烯过渡态等排体的化合物的合成，酶抑制和抗病毒活性。

  摘要：

  制备了许多含有二羟基乙烯等排物的潜在HIV蛋白酶抑制肽，并评估了它们在细胞培养物中的酶结合亲和力和抗病毒活性。从先前报道的活性肽A的模板中，评估在N-和C-末端基团上的修饰以潜在维持所得肽的良好抑制活性。在发现的活性肽中，肽X显示出有效的酶抑制活性。有趣的是，先前报道的用于制备非常活性的HIV蛋白酶抑制肽的有效的1（S）-氨基-2（R）-羟基茚满C-末端基团不能应用于肽XVIII的模板。以肽A的X射线晶体结构为起点，研究了肽XVIII的分子模型，以便研究活性部位裂口中肽XVIII的可能构象。获得了肽A和XVIII的相对结合构象，尽管在本报告中对许多同类肽的结合亲和力差的原因尚不十分清楚。然而，更重要的是，发现肽XVIII在HIV-1 / PBMC分析中显示出比参考肽A更有效的抗病毒活性，参考肽A先前据报道在该分析中的功效与逆转录酶抑制剂AZT大致相等。尽管在本报告中对许多同类肽的结合亲和力

  DOI：

  10.1021/jm00060a001

文献信息

• AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF
  申请人：Ogura Hironobu

  公开号：US20100190754A1

  公开（公告）日：2010-07-29

  An azolylmethylidenehydrazine derivative represented by the formula (I) wherein Ar is an aryl group optionally having substituent(s) or a heteroaryl group optionally having substituent(s), R 1 and R 2 are the same or different and each is an alkyl group, a cycloalkyl group, an aralkyl group optionally having substituent(s), an aryl group optionally having substituent(s), a heteroarylalkyl group optionally having substituent(s), or R 1 and R 2 are bonded to each other to form a nitrogen-containing heterocyclic group optionally having substituent(s), and X is CH or a nitrogen atom, or a pharmacologically acceptable salt thereof is useful as a medicament, particularly as an antifungal agent, or an anti-inflammatory agent or an antiallergic agent.

  一种以式(I)表示的氮杂环甲基亚唑啉衍生物，其中Ar是一个芳基基团，可选择地具有取代基，或者是一个杂芳基基团，可选择地具有取代基；R1和R2相同或不同，每个都是一个烷基基团、环烷基基团、可选择地具有取代基的芳基烷基基团、可选择地具有取代基的芳基基团、可选择地具有取代基的杂芳基烷基基团，或者R1和R2彼此连接形成一个可选择地具有取代基的含氮杂环基团；X是CH或氮原子；或其药学上可接受的盐，可用作药物，特别是作为抗真菌药物、抗炎药物或抗过敏药物。
• AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF
  申请人：KAKEN PHARMACEUTICAL CO., LTD.

  公开号：EP2168951A1

  公开（公告）日：2010-03-31

  An azolylmethylidenehydrazine derivative represented by the formula (I) wherein Ar is an aryl group optionally having substituent(s), a heteroaryl group optionally having substituent(s) or a heteroaryl group optionally having substituent(s), R1 and R2 are the same or different and each is an alkyl group, a cycloalkyl group, an aralkyl group optionally having substituent(s), an aryl group optionally having substituent(s), a heteroarylalkyl group optionally having substituent(s), or R1 and R2 are bonded to each other to form a nitrogen-containing heterocyclic group optionally having substituent(s), and X is CH or a nitrogen atom, or a pharmacologically acceptable salt thereof is useful as a medicament, particularly as an antifungal agent, or an anti-inflammatory agent or an antiallergic agent.

  由式 (I) 代表的偶氮亚甲基肼衍生物 其中 Ar 是可选具有取代基的芳基、可选具有取代基的杂芳基或可选具有取代基的杂芳基、 R1 和 R2 相同或不同，且各自为烷基、环烷基、任选具有取代基的芳烷基、任选具有取代基的芳基、任选具有取代基的杂芳基，或 R1 和 R2 相互键合形成任选具有取代基的含氮杂环基，且 X 为 CH 或氮原子、 或其药理上可接受的盐可用作药物，特别是抗真菌剂、抗炎剂或抗过敏剂。
• Some Organosilicon Compounds Derived from Aryl Ethers
  作者：KATASHI OITA、HENRY GILMAN

  DOI：10.1021/jo01115a022

  日期：1956.9
• Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors
  作者：I. Islam、K. Y. Ng、K. T. Chong、T. J. McQuade、J. O. Hui、K. F. Wilkinson、B. D. Rush、M. J. Ruwart、R. T. Borchardt、J. F. Fisher

  DOI：10.1021/jm00028a013

  日期：1994.1

  The outstanding limitations to the oligopeptide as a therapeutic agent are poor oral availability and rapid biliary clearance. To address these concerns a series of eight peptidic HIV-1 protease inhibitors containing the structural segment of the vitamin biotin have been prepared. These have been evaluated with regard to the hypothesis that this vitamin would cloak the peptidic character of these oligopeptides, and thus impart to these inhibitors the potential for absorption and distribution via biotin transporters and receptors. By iterative optimization about a -Chal psi[CH- (OH)CH(OH)]Val- core inhibitory insert, three particularly potent inhibitors (K-i less than or equal to 10 nM) of the HIV-1 protease were obtained. Although excellent cell culture antiviral activity is observed for other peptidic protease inhibitors of comparable affinity, none in this series exhibited satisfactory antiviral activity. This failure is-attributed to the incompatibility of the hydrophilic and hydrogen-bonding biotin segment, with the facile membrane permeability and intracellular access presumably required for antiviral activity. The ability of the biotin to cloak the peptide, and thus render the overall appearance of the conjugate as that of a vitamin, was evaluated. Four of this series were evaluated for recognition by the Caco-2 cell intestinal biotin transporter, None inhibited competitively biotin uptake, indicating a lack of recognition. A vitamin may bind to a specific protein carrier, and thus attain an improved serum profile (by resistance to biliary clearance) and advantageous delivery to cells. Therefore, the serum concentrations of three were evaluated following an iv bolus in a rat model for serum clearance. One of the three protease inhibitors (L-idonamide, 6-cyclohexyl-2,5,6-trideoxy-2-(1-methylethyl)-5-[[3-methyl-1-oxo-2-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]butyl]amino]-N-[2-methyl-1-[[(2-pyridinylmethyl)amino] carbonyl]butyl]-, [3aS-[3a alpha,4 beta(1R*,2R*;3R*),6a alpha]]-) sustained a more than 5-fold increase in serum concentration at all time points relative to the benchmark structure. The remaining two had serum concentrations at least equal to the benchmark, suggestive of improved resistance to clearance. One(L-idonamide, 6-cyclohexyl-2,5,6-trideoxy-5-[[2-[[5-(hexahydro-2-oxo-1H-thieno-[3,4-d]imidazol-4-yl)pentyl]thio]benzoyl]amino]-2-(1-methylethyl)-N-[2-methyl-1-[[(2-pyridinyl- methyl)amino]carbonyl]butyl]-, [3aS-[3a alpha,4 beta(1R*,2R*),6a alpha]]-) was prepared as a complex with the biotin-binding protein avidin. Avidin may resemble an endogenous serum biotin carrier protein. The antiviral activity (evaluated in an H9-HTLV(IIIB) acute HIV-1 infection assay) of the inhibitor and the avidin complex was identical. This suggests that the avidin-inhibitor complex is capable of cell internalization. Although the weak antiviral activity of these biotinylated inhibitors precludes consideration as practical HIV therapeutics, the overall data remain suggestive of vitamin cloaking of oligopeptides as a strategy of potential value.
• The Preparation of Some Polyalkoxy Ethers of the Isomeric Hydroxybenzoic Acids¹
  作者：R. W. Bost、Meldrum B. Winstead

  DOI：10.1021/ja01127a058

  日期：1952.4